WASHINGTON (Reuters) - GlaxoSmithKline Plc’s diabetes drug Avandia stimulates the action of a cell that drives the normal bodily process of reabsorbing bone, making bones more apt to break, researchers said on Sunday.Previous studies had established a heightened risk for bone fractures among women taking Avandia, the top-selling diabetes drug. The new research, published in the journal Nature Medicine, offered an explanation.
